adenine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Q | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Smith, WW | 1 |
| Zhu, Y | 1 |
| Liu, Z | 1 |
| Mercado, G | 1 |
| Castillo, V | 1 |
| Soto, P | 1 |
| López, N | 1 |
| Axten, JM | 1 |
| Sardi, SP | 1 |
| Hoozemans, JJM | 1 |
| Hetz, C | 1 |
| Stasi, MA | 1 |
| Minetti, P | 1 |
| Lombardo, K | 1 |
| Riccioni, T | 1 |
| Caprioli, A | 1 |
| Vertechy, M | 1 |
| Di Serio, S | 1 |
| Pace, S | 1 |
| Borsini, F | 2 |
| Fuzzati-Armentero, MT | 1 |
| Cerri, S | 1 |
| Levandis, G | 1 |
| Ambrosi, G | 1 |
| Montepeloso, E | 1 |
| Antoninetti, G | 1 |
| Blandini, F | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Volpini, R | 1 |
| Costa, G | 1 |
| Simola, N | 1 |
| Pinna, A | 1 |
| Frau, L | 1 |
| Wardas, J | 1 |
| Khairnar, AS | 1 |
| Schintu, N | 1 |
| Morelli, M | 1 |
| GOMIRATO, G | 1 |
| HYDEN, H | 1 |
| Rose, S | 1 |
| Ramsay Croft, N | 1 |
| Jenner, P | 1 |
7 other studies available for adenine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models.
Topics: Adenine; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Astrocytes; Aut | 2021 |
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease.
Topics: Adenine; Animals; Disease Models, Animal; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, I | 2018 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas | 2015 |
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Topics: Adenine; Animals; Drug Delivery Systems; Drug Synergism; Levodopa; Male; Neurons; Neuroprotective Ag | 2015 |
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Brain; Immunohistoche | 2011 |
A BIOCHEMICAL GLIA ERROR IN THE PARKINSON DISEASE.
Topics: Adenine; Cytosine; Globus Pallidus; Guanine; Neurochemistry; Neuroglia; Neurons; Nucleic Acids; Park | 1963 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopam | 2007 |